MX2008003230A - Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b. - Google Patents

Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.

Info

Publication number
MX2008003230A
MX2008003230A MX2008003230A MX2008003230A MX2008003230A MX 2008003230 A MX2008003230 A MX 2008003230A MX 2008003230 A MX2008003230 A MX 2008003230A MX 2008003230 A MX2008003230 A MX 2008003230A MX 2008003230 A MX2008003230 A MX 2008003230A
Authority
MX
Mexico
Prior art keywords
combination
pharmaceutical composition
oral pharmaceutical
complex vitamins
ketorolac
Prior art date
Application number
MX2008003230A
Other languages
English (en)
Inventor
Gustavo Barranco Hernandez
Juan Aurelio Senosiain Aguilar
E Raul Garcia Salgado Lopez
M Angelica Arzola Paniagua
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Priority to MX2008003230A priority Critical patent/MX2008003230A/es
Priority to ARP090100696A priority patent/AR070542A1/es
Priority to ES09717937.8T priority patent/ES2526359T3/es
Priority to US12/921,317 priority patent/US20110059171A1/en
Priority to CA2717900A priority patent/CA2717900C/en
Priority to PL09717937T priority patent/PL2255803T4/pl
Priority to BRPI0908988-8A priority patent/BRPI0908988A2/pt
Priority to EP09717937.8A priority patent/EP2255803B1/en
Priority to PCT/IB2009/000413 priority patent/WO2009109836A1/es
Priority to PE2009000335A priority patent/PE20091592A1/es
Publication of MX2008003230A publication Critical patent/MX2008003230A/es
Priority to DO2010000265A priority patent/DOP2010000265A/es
Priority to EC2010010442A priority patent/ECSP10010442A/es
Priority to CR11668A priority patent/CR11668A/es
Priority to CO10109151A priority patent/CO6290082A1/es
Priority to HN2010001775A priority patent/HN2010001775A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica oral sólida que comprende la combinación de ketorolaco y Complejo B, compuesto entre otros de tiamina, piridoxina y cianocobalamina (vitaminas B1, B6 y B12, respectivamente) y/o sus sales farmacéuticamente aceptables, adicionalmente, vehículos y/o excipientes farmacéuticamente aceptables; el proceso de fabricación de la composición y el uso de dicha composición con actividad terapéutica sinérgica, indicada para el tratamiento de dolor de moderado a severo o neuralgias de diversas localización.
MX2008003230A 2008-03-07 2008-03-07 Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b. MX2008003230A (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
MX2008003230A MX2008003230A (es) 2008-03-07 2008-03-07 Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.
ARP090100696A AR070542A1 (es) 2008-03-07 2009-02-27 Composicion farmaceutica oral microencapsulada que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b
EP09717937.8A EP2255803B1 (en) 2008-03-07 2009-03-04 Oral galenic formulation including ketorolac and b-complex vitamins, in which vitamin b6 is in an outer layer separated from the rest of the active principles
US12/921,317 US20110059171A1 (en) 2008-03-07 2009-03-04 Oral galenic formulation including ketorolac and b-complex vitamins, in which vitamin b6 is in an outer layer separated from the rest of the active principles
CA2717900A CA2717900C (en) 2008-03-07 2009-03-04 Oral galenic formulation including ketorolac and b-complex vitamins, in which vitamin b6 is in an outer layer separated from the rest of the active principles
PL09717937T PL2255803T4 (pl) 2008-03-07 2009-03-04 Doustny preparat galenowy zawierający ketorolak i witaminy z grupy B, w którym witamina B6 znajduje się w warstwie zewnętrznej oddzielonej od pozostałych składników czynnych
BRPI0908988-8A BRPI0908988A2 (pt) 2008-03-07 2009-03-04 formulação galênica oral incluindo cetorolaco e vitaminas do complexo b, em que a vitamina b6 está em uma camada externa separada do resto dos princípios ativos
ES09717937.8T ES2526359T3 (es) 2008-03-07 2009-03-04 Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos
PCT/IB2009/000413 WO2009109836A1 (es) 2008-03-07 2009-03-04 Formulación galénica oral que comprende ketorolaco y vitaminas del complejo b, en la que la vitamina b6 se encuentra en una capa externa separada del resto de principios activos
PE2009000335A PE20091592A1 (es) 2008-03-07 2009-03-05 Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b
DO2010000265A DOP2010000265A (es) 2008-03-07 2010-09-01 Formulacion galenica oral que comprende ketorolaco y vitaminas del complejo b, en la que la vitamina b6 se encuentra em una capa externa separada del resto de principios activos
EC2010010442A ECSP10010442A (es) 2008-03-07 2010-09-02 Formulación galénica oral que comprende ketorolaco y vitaminas del complejo b, en la que la vitamina b6 se encuentra en una capa externa separada del resto de principios activos
CR11668A CR11668A (es) 2008-03-07 2010-09-02 Formulacion galenica oral que comprende ketorolaco y vitaminas del complejo b, en la que la vitamina b6 se encuentra en una capa externa separada del resto de principios activos
CO10109151A CO6290082A1 (es) 2008-03-07 2010-09-03 Composicion farmaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b
HN2010001775A HN2010001775A (es) 2008-03-07 2010-09-07 Composicion farmaceutica oral que comprende la combinacion de una sal de keterolaco y vitaminas del complejo b

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2008003230A MX2008003230A (es) 2008-03-07 2008-03-07 Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.

Publications (1)

Publication Number Publication Date
MX2008003230A true MX2008003230A (es) 2009-09-07

Family

ID=41055594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008003230A MX2008003230A (es) 2008-03-07 2008-03-07 Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.

Country Status (15)

Country Link
US (1) US20110059171A1 (es)
EP (1) EP2255803B1 (es)
AR (1) AR070542A1 (es)
BR (1) BRPI0908988A2 (es)
CA (1) CA2717900C (es)
CO (1) CO6290082A1 (es)
CR (1) CR11668A (es)
DO (1) DOP2010000265A (es)
EC (1) ECSP10010442A (es)
ES (1) ES2526359T3 (es)
HN (1) HN2010001775A (es)
MX (1) MX2008003230A (es)
PE (1) PE20091592A1 (es)
PL (1) PL2255803T4 (es)
WO (1) WO2009109836A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619344C1 (ru) * 2016-03-01 2017-05-15 Петр Александрович Попов Способ лечения невралгии
TR201702630A2 (tr) 2017-02-22 2018-09-21 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Alfa li̇poi̇k asi̇t ve suda çözünür vi̇tami̇nler i̇çeren oral farmasöti̇k bi̇leşi̇mler
EP3366291A1 (en) * 2017-02-22 2018-08-29 Montero Gida Sanayi Ve Ticaret A.S. Solid oral pharmaceutical compositions comprising alpha lipoic acid and water-soluble vitamins
US20230414545A1 (en) 2020-12-04 2023-12-28 Laboratorios Silanes S.A. De C.V. Fixed combination medicine for the control and management of neuropathic pain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4492M (es) * 1965-07-07 1966-10-10
US4564614A (en) * 1984-10-11 1986-01-14 Pfizer Inc. Antiinflammatory methods
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US6051587A (en) * 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US9668972B2 (en) * 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
MXPA02010828A (es) * 2002-11-04 2004-07-16 Leopoldo Espinosa Abdala Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.
US7335384B2 (en) * 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
DOP2007000055A (es) * 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas

Also Published As

Publication number Publication date
ES2526359T3 (es) 2015-01-09
ECSP10010442A (es) 2010-10-30
EP2255803B1 (en) 2014-09-17
PL2255803T3 (pl) 2015-05-29
EP2255803A1 (en) 2010-12-01
CO6290082A1 (es) 2011-06-20
WO2009109836A1 (es) 2009-09-11
HN2010001775A (es) 2013-01-15
EP2255803A4 (en) 2011-06-29
PE20091592A1 (es) 2009-11-11
CA2717900A1 (en) 2009-09-11
PL2255803T4 (pl) 2015-05-29
US20110059171A1 (en) 2011-03-10
DOP2010000265A (es) 2010-09-30
CA2717900C (en) 2016-05-10
BRPI0908988A2 (pt) 2020-08-04
AR070542A1 (es) 2010-04-14
CR11668A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
NZ714963A (en) Compositions and methods for treating anemia
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
JP2010536849A5 (es)
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2009007630A (es) Derivados de tiazolidina y metodos para su preparacion.
HRP20130139T1 (hr) Mipo inhibitori za lijeäśenje huntingtonove bolesti i multiple sistemske atrofije
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
WO2013085849A3 (en) Sulfate esters of noribogaine
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2009006574A (es) Tratamiento de cancer de pulmon.
MX2008003230A (es) Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2010002835A3 (en) Vinpocetine and eburnamonine derivatives for promoting bone growth
FI3345604T3 (fi) Nalmefeeni alkoholikulutuksen vähentämiseksi spesifisissä kohdepopulaatioissa
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
FG Grant or registration